Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2016 1
2017 2
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5).
Ólafsdóttir AF, Bolinder J, Heise T, Polonsky W, Ekelund M, Wijkman M, Pivodic A, Ahlén E, Schwarcz E, Nyström T, Hellman J, Hirsch IB, Lind M. Ólafsdóttir AF, et al. Among authors: ahlen e. Diabetes Obes Metab. 2021 Feb;23(2):619-630. doi: 10.1111/dom.14257. Epub 2020 Dec 10. Diabetes Obes Metab. 2021. PMID: 33200487 Free PMC article. Clinical Trial.
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, Schwarz E, Ólafsdóttir AF, Frid A, Wedel H, Ahlén E, Nyström T, Hellman J. Lind M, et al. Among authors: ahlen e. JAMA. 2017 Jan 24;317(4):379-387. doi: 10.1001/jama.2016.19976. JAMA. 2017. PMID: 28118454 Clinical Trial.
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3).
Dahlqvist S, Ahlén E, Filipsson K, Gustafsson T, Hirsch IB, Tuomilehto J, Imberg H, Ahrén B, Attvall S, Lind M. Dahlqvist S, et al. Among authors: ahlen e. BMJ Open Diabetes Res Care. 2018 Feb 24;6(1):e000464. doi: 10.1136/bmjdrc-2017-000464. eCollection 2018. BMJ Open Diabetes Res Care. 2018. PMID: 29527308 Free PMC article.